|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since p53 protein has become recognized biomarker for both diagnostic and therapeutic purposes in oncological diseases with particular relevance for bladder cancer, it is highly desirable to search for a novel sensing tool for detecting the patient's p53 level at the early stage.
|
29031295 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, Rb knockout and knockdown result in autophagy and apoptosis inhibition via suppressing p53 and caspase-3 signaling pathways, enhancing bladder cancer development in vitro and in vivo.
|
28259945 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mRNA expression levels of the indicated genes, including CCND1, CCNA1, EGFR, AR, CX3CL1, CXCL6, and CXCL1, were significantly increased in urinary bladder from CG and bladder cancer (BC) patients compared with healthy controls, while TP53 was decreased.
|
28285559 |
2017 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that YB-1 translocates to the nucleus coordinately with p53 expression and is involved in gemcitabine resistance in bladder cancer.
|
28714514 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
To prove the potential utility of this device, P53 was tested as a functional target in the bladder cancer cell models.
|
27766041 |
2016 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations are common in low-grade BC, while TP53 mutation or loss of RB1 is associated with muscle-invasive BC.
|
26924873 |
2016 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysing only previously reported point mutations, TERT mutations were found in 55% of patients with bladder cancer (independent of stage), FGFR3 mutations in 30% of patients with bladder cancer, PIK3CA in 14% and TP53 mutations in 12% of patients with bladder cancer.
|
26901314 |
2016 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transfection of dsP53-285 into human bladder cancer cell lines T24 and EJ readily activate wild-type p53 expression by targeting promoter.
|
27012825 |
2016 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-21 regulates proliferation and migration of bladder cancer cells and cross talk with PTEN and p53 in bladder cancer.
|
26230405 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that combined CDKN1A-TP53 loss would make bladder cancer sensitive to combined treatment with gemcitabine and Chk1 inhibitor.
|
25349305 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since members of ING family were discovered as TSGs in different cancer types, it was aimed to analyze the chromosome 13q33-34 region, ING1 and p53 genes in bladder cancer.
|
25324173 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
|
26254388 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
|
26653553 |
2015 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, these findings indicate an association between p53 codon72 polymorphism and bladder cancer risk in Bangladeshi population.
|
25801242 |
2015 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the outcome of reactivating p53 in controlling bladder cancer development is limited by its efficiency and specificity of peptide delivery, especially in metastatic animal models.
|
26462022 |
2015 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent developments in the field of molecular mutational pathway analyses based on next generation sequencing technology together with classic data derived from the description of mutations in the FGFR3 (fibroblast growth factor receptor 3) gene, mutations on TP53 gene, and cDNA technology profiling data gives support to a differentiated taxonomy of bladder cancer.
|
25654736 |
2015 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p63 and p73 expressions have been investigated in a variety of human tumours including bladder carcinomas; yet, this is the first study to simultaneously analyse the transcriptional levels of all p53 family members in bladder cancer.
|
24213852 |
2014 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We carried out an in depth assessment of associations between common germline variants in the TP53 pathway and bladder cancer risk.
|
24818791 |
2014 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examined whether FKA could inhibit bladder cancer development and progression in vivo in the UPII-SV40T transgenic model that resembles human urothelial cell carcinoma (UCC) with defects in the p53 and the retinoblastoma (Rb) protein pathways.
|
24121102 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.
|
23356517 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TP53 codon72 polymorphism appears to play a crucial role in determining the association between TP53 haplotype and the incidence and prognosis of bladder cancer.
|
22178231 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subgroup analyses by ethnicity showed that TP53 Arg72Pro polymorphism contributed to bladder cancer risk in East Asians in three genetic models (For Pro vs. Arg, Fixed-effects OR 1.18, 95 % CI 1.05-1.32; For ProPro vs. ArgArg, Fixed-effects OR 1.40, 95 % CI 1.11-1.77; For ProPro vs. ArgPro/ArgArg, Fixed-effects OR 1.32, 95 % CI 1.07-1.62).
|
23184052 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
M-ds-P21 induces cell apoptosis in bladder cancer T24 cells through P53 independent pathway.
|
23575075 |
2013 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A20 bound to p53 to form complexes in bladder cancer tissue and bladder polypoid tissue.
|
23471665 |
2013 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that p53 Arg72Pro polymorphism is associated with increased risk of bladder cancer in Asians.
|
23073555 |
2013 |